Medindia

X

Telik Regains Compliance With Minimum Bid Price Requirement

Friday, April 23, 2010 General News J E 4
Advertisement


PALO ALTO, Calif., April 22 Telik, Inc. (Nasdaq: TELK) today announced that it has received from The Nasdaq Stock Market notification that Telik has regained compliance with the minimum bid price rule for continued listing on The Nasdaq Capital Market because the bid price of Telik's common stock has closed at $1.00 per share or greater for at least 10 consecutive business days.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced drug candidates in clinical development are TELINTRA®, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA®, a tumor-activated prodrug for the treatment of advanced non-small cell lung cancer and ovarian cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Fraunhofer Centers in Newark, DE, and at Boston Un...
S
WellPoint's Reuters Response